For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to ...
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...
The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a treatment for depression. A clinic in Denver is looking to help those ...
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
A new study found that retirees who drank moderately had fewer depression symptoms than non-drinkers, but retirees who drank ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.